HONG KONG, Sept. 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced the presentation of positive overall survival (OS) results from the randomized, double-blind, multicenter, registrational Phase III HARMONi-2 study (AK112-303) at the 2026 World Conference on Lung Cancer...
Hence then, the article about oral presentation ivonescimab versus pembrolizumab in first line pd l1 positive nsclc positive overall survival results from harmoni 2 at wclc 2026 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Oral Presentation: Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 at WCLC 2026 )
Also on site :
- Pulitzer-Winning Author’s Novel, Written in a Home Basement, Ranked ‘Greatest Book of the Last 20 Years’
- Anthropologie’s Multicolored Glass and Stone Hoops Add Vintage-Style Elegance to Any Look for Just $30
- Walmart’s ‘Whimsical’ Boucle Mushroom Storage Ottoman Looks ‘Trendy’ and ‘High-End,’ But It’s Now Under $30